Table 2.

Pathology Results. The outcomes are measured regarding local recurrence, distant metastasis, downstaging of the tumour (T & N, T, N), pathological complete response (pCR), and three-year disease-free survival

Variable		Group A (Neoadjuvant chemotherapy) (n = 146)	Group B (Standard-of-care) (n = 138)	Relative Risk (95% CI)	P value
Down Stage (T & N)	Yes	118 (80.82%)	84 (60.87%)	2.040 (1.388 to 3.031)	< 0.001
	No	28 (19.18%)	54 (39.13%)
Down Stage (T)	Yes	106 (72.60%)	79 (57.24%)	1.561 (1.130 to 2.171)	0.009
	No	40 (27.40%)	59 (42.75%)
Down Stage (N)	Yes	80 (54.79%)	57 (41.3%)	1.298 (1.037 to 1.653)	0.025
	No	66 (45.21%)	81 (58.70%)
Pathological Complete Response (pCR)	Yes	38 (26.03%)	21 (15.22%)	1.136 (1.018 to 1.299)	0.030
	No	108 (73.97%)	117 (84.78%)